alexa CG210 Enables Finasteride 1mg Users to Further Improve Hair Pattern: A Randomized, Double-Blind, Placebo-Controlled Pilot Study | OMICS International | Abstract
ISSN: 2167-0951

Hair Therapy & Transplantation
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

CG210 Enables Finasteride 1mg Users to Further Improve Hair Pattern: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Akira Takeda1,2, Akio Sato2,3, Lei Zhang4, Saad Harti4, Geert Cauwenbergh4 and JiaWei Liu4,5*

1Department of Plastic and Aesthetic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan

2Department of Regenerative Medicine Plastic and Reconstructive Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan

3Tokyo Memorial Clinic, Tokyo 151-0053, Japan

4Legacy Healthcare, Route de la Corniche 9B, 1066 Epalinges, Switzerland

5Teaching staff, PPCR course, Harvard Medical School, USA

Corresponding Author:
JiaWei Liu
Teaching staff, PPCR course
Harvard Medical School
Legacy Healthcare
Route de la Corniche 9B
1066 Epalinges, Switzerland
Tel: +41 78 8849782
Fax: +41 21 6534484
E-mail: [email protected]

Received Date: June 24, 2013; Accepted Date: August 01, 2013; Published Date: August 03, 2013

Citation: Takeda A, Sato A, Zhang L, Harti S, Cauwenbergh G, et al. (2013) CG210 Enables Finasteride 1mg Users to Further Improve Hair Pattern: A Randomized, Double-Blind, Placebo-Controlled Pilot Study of a Novel Product. Hair Ther Transplant 3:107. doi:10.4172/2167-0951.1000107

Copyright: © 2013 Takeda A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: The efficacy of Finasteride 1mg, the first-line treatment for male Androgenetic Alopecia (AGA), tends to reach a plateau after several years’ treatment. Up to date, effective and safe options are limited because current modalities managing AGA have so far not taken into account the two key issues particularly relevant to excessive hair loss: the early onset of catagen (due to premature hair follicular cell apoptosis) and the frequently observed sustained micro-inflammation in the scalp.

Objective: We investigated the potential synergic effect of combining the oral finasteride 1mg, acting on conversion of testosterone to 5α-dihydrotestosterone, with CG210, a novel topical anti-hair loss product, acting on premature apoptosis and micro-inflammation in the scalp.

Methods: We designed a 12-month, randomized, double-blind, placebo-controlled trial using CG210 in twenty AGA volunteers already using Finasteride 1mg for at least three years. Hair diameters were assessed and compared for hair pattern improvement.

Results: The increase of hair diameter in the “Finasteride 1 mg + topical CG210” group was 37.7% more than that in “Finasteride 1 mg + topical placebo” group (p=0.002). No side effect was observed. Conclusion: In addition to 5α-reductase inhibitors, our study puts forward the approach to simultaneously address both premature cell apoptosis in the hair follicles and micro-inflammation in the scalp. The results suggest an efficient mode in the management of AGA with improved efficacy over the currently referenced modality. Furthermore, the studied topical CG210 may represent a new option for alopecia subjects, including those under finasteride 1mg, to improve their hair pattern.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7